Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 1
1994 5
1995 5
1996 1
1997 6
1998 3
1999 3
2000 6
2001 4
2002 6
2003 2
2004 1
2005 9
2006 4
2007 4
2008 6
2009 5
2010 2
2011 7
2012 7
2013 5
2014 10
2015 4
2016 10
2017 3
2018 10
2019 12
2020 8
2021 12
2022 9
2023 7
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Prostate Adenocarcinoma with Neuroendocrine Differentiation"
Page 1
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.
Zhao SG, Sperger JM, Schehr JL, McKay RR, Emamekhoo H, Singh A, Schultz ZD, Bade RM, Stahlfeld CN, Gilsdorf CS, Hernandez CI, Wolfe SK, Mayberry RD, Krause HM, Bootsma M, Helzer KT, Rydzewski N, Bakhtiar H, Shi Y, Blitzer G, Kyriakopoulos CE, Kosoff D, Wei XX, Floberg J, Sethakorn N, Sharifi M, Harari PM, Huang W, Beltran H, Choueiri TK, Scher HI, Rathkopf DE, Halabi S, Armstrong AJ, Beebe DJ, Yu M, Sundling KE, Taplin ME, Lang JM. Zhao SG, et al. J Clin Invest. 2022 Nov 1;132(21):e161858. doi: 10.1172/JCI161858. J Clin Invest. 2022. PMID: 36317634 Free PMC article.
BackgroundNeuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate cancer.MethodsWe performed analytical validation of a Circulating Tumor Cell (CTC) multiplex RNA qPCR a …
BackgroundNeuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management …
GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.
Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, Langfort R, Waloszczyk P, Biernat W, Lasota J, Wang Z. Miettinen M, et al. Am J Surg Pathol. 2014 Jan;38(1):13-22. doi: 10.1097/PAS.0b013e3182a0218f. Am J Surg Pathol. 2014. PMID: 24145643 Free PMC article.
GATA3 is a transcription factor important in the differentiation of breast epithelia, urothelia, and subsets of T lymphocytes. ...Common positivity was found in skin adnexal tumors (100%), mesothelioma (58%), salivary gland (43%), and pancreatic (37%) ductal carcinomas, wh …
GATA3 is a transcription factor important in the differentiation of breast epithelia, urothelia, and subsets of T lymphocytes. ...Com …
Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H, Samarska I, Lu J, Faisal F, Maughan BL, Murali S, Asrani K, Alshalalfa M, Antonarakis ES, Epstein JI, Joshu CE, Schaeffer EM, Mosquera JM, Lotan TL. Kaur H, et al. Prostate. 2020 Sep;80(12):1012-1023. doi: 10.1002/pros.24035. Epub 2020 Jul 10. Prostate. 2020. PMID: 32649013 Free PMC article.
BACKGROUND: Small cell neuroendocrine (NE) carcinomas of the prostate classically lose androgen receptor (AR) expression, may harbor loss of the RB1, TP53, and PTEN tumor suppressor genes, and are associated with a poor prognosis. ...CONCLUSION: NE differe …
BACKGROUND: Small cell neuroendocrine (NE) carcinomas of the prostate classically lose androgen receptor (AR) expressio …
MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D. Yasumizu Y, et al. Nat Commun. 2020 Jan 17;11(1):338. doi: 10.1038/s41467-019-14219-6. Nat Commun. 2020. PMID: 31953400 Free PMC article.
Neuroendocrine prostate cancer (NEPC) is an aggressive malignancy with no effective targeted therapies. The oncogenic MUC1-C protein is overexpressed in castration-resistant prostate cancer (CRPC) and NEPC, but its specific role is unknown. ...
Neuroendocrine prostate cancer (NEPC) is an aggressive malignancy with no effective targeted therapies. The oncogenic MUC1-C p …
PEG10 is associated with treatment-induced neuroendocrine prostate cancer.
Kim S, Thaper D, Bidnur S, Toren P, Akamatsu S, Bishop JL, Colins C, Vahid S, Zoubeidi A. Kim S, et al. J Mol Endocrinol. 2019 Jul 1;63(1):39-49. doi: 10.1530/JME-18-0226. J Mol Endocrinol. 2019. PMID: 31013476
Neuroendocrine (NE) differentiation of advanced prostate adenocarcinoma following androgen receptor (AR) axis-directed therapy is becoming increasingly recognized. ...Overall, these observations indicate that PEG10 is an AR-repressed gene which …
Neuroendocrine (NE) differentiation of advanced prostate adenocarcinoma following androgen receptor (AR) axis-di …
Lineage plasticity-mediated therapy resistance in prostate cancer.
Blee AM, Huang H. Blee AM, et al. Asian J Androl. 2019 May-Jun;21(3):241-248. doi: 10.4103/aja.aja_41_18. Asian J Androl. 2019. PMID: 29900883 Free PMC article. Review.
Lineage reprogramming in response to hormone therapy represents a key mechanism that is increasingly observed. The studies in this area have revealed specific combinations of alterations present in adenocarcinomas that provide cells with the ability to transdifferen …
Lineage reprogramming in response to hormone therapy represents a key mechanism that is increasingly observed. The studies in this ar …
Aggressive variants of castration-resistant prostate cancer.
Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA. Beltran H, et al. Clin Cancer Res. 2014 Jun 1;20(11):2846-50. doi: 10.1158/1078-0432.CCR-13-3309. Epub 2014 Apr 11. Clin Cancer Res. 2014. PMID: 24727321 Free PMC article. Review.
Biopsies performed in such patients may vary, ranging from poorly differentiated carcinomas to mixed adenocarcinoma-small cell carcinomas to pure small cell carcinomas. These aggressive tumors often demonstrate low or absent AR protein expression and, …
Biopsies performed in such patients may vary, ranging from poorly differentiated carcinomas to mixed adenocarcinoma-small c …
Neuroendocrine differentiation of prostate cancer leads to PSMA suppression.
Bakht MK, Derecichei I, Li Y, Ferraiuolo RM, Dunning M, Oh SW, Hussein A, Youn H, Stringer KF, Jeong CW, Cheon GJ, Kwak C, Kang KW, Lamb AD, Wang Y, Dong X, Porter LA. Bakht MK, et al. Endocr Relat Cancer. 2018 Nov 23;26(2):131-146. doi: 10.1530/ERC-18-0226. Endocr Relat Cancer. 2018. PMID: 30400059
Prostate-specific membrane antigen (PSMA) is overexpressed in most prostate adenocarcinoma (AdPC) cells and acts as a target for molecular imaging. However, some case reports indicate that PSMA-targeted imaging could be ineffectual for delineation of neuro …
Prostate-specific membrane antigen (PSMA) is overexpressed in most prostate adenocarcinoma (AdPC) cells and acts as a t …
The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
Mosca A, Berruti A, Russo L, Torta M, Dogliotti L. Mosca A, et al. J Endocrinol Invest. 2005;28(11 Suppl International):141-5. J Endocrinol Invest. 2005. PMID: 16625864 Review.
Most of the conventional adenocarcinomas of the prostate display focal neuroendocrine (NE) differentiation at diagnosis, usually revealed by immunohistochemistry as solitary or clusters of cells, in the context of predominantly exocrine tumors. Even th …
Most of the conventional adenocarcinomas of the prostate display focal neuroendocrine (NE) differentiation at di …
Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation.
Minagawa H, Kawai T, Matsumoto A, Makino K, Sato Y, Nagasaka K, Tokura M, Tanaka N, Ito E, Yamada Y, Nakamura M, Yamada D, Suzuki M, Murata T, Kume H. Minagawa H, et al. BMC Urol. 2021 Jan 7;21(1):8. doi: 10.1186/s12894-020-00779-z. BMC Urol. 2021. PMID: 33413292 Free PMC article.
High levels of PSA and NSE were observed, and prostate biopsy revealed an adenocarcinoma with neuroendocrine differentiation. ...CONCLUSIONS: We successfully treated a rare case of dermatomyositis associated with prostate adenocarcinom …
High levels of PSA and NSE were observed, and prostate biopsy revealed an adenocarcinoma with neuroendocrine …
162 results